Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ginkgo Bioworks Holdings (DNA) Stock Price & Analysis

DNA Stock Chart & Stats

MX$117.00MX$0.00(0.00%)
At close:
Mex$120Mex$140Mex$1602 Jul2 Sep
Day’s Range
MXN 117.00 - MXN 135.80
52-Week Range
MXN 110.00 - MXN 289.00
Previous Close
MXN 117.00
Volume
0
Average Volume (3M)
0
Market Cap
MXN 14.19B
Enterprise Value
MXN 714.39M
Total Cash (Recent Filing)
MXN 302.16M
Total Debt (Recent Filing)
MXN 404.11M
Price to Earnings (P/E)
―
Beta
-0.34
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
-12.74
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

ADME-One Price Advantage

ADME-One’s substantially lower price, combined with reported validation against industry peers, could make Ginkgo’s service more accessible to biotech customers. If performance remains credible, this cost advantage may support adoption, strengthen differentiation, and improve the platform’s long-term commercial reach.

Autonomous Lab Expansion And Contracts

Academic and national-lab engagements provide external validation for Ginkgo’s autonomous-lab platform while expanding its deployment footprint. Nebula’s increased capacity and continuous operation can build engineering know-how, create reference sites, and support broader adoption of productized biological research infrastructure.

Liquidity And Lower Cloud Commitments

A sizeable cash position gives Ginkgo time to execute its platform strategy and fund operations while pursuing cost efficiencies. The reduced Google Cloud obligation also lowers future contractual cash requirements, improving financial flexibility and preserving more resources for autonomous labs, software, and commercial development.

Bears Say

Sharp Revenue Contraction

The magnitude and persistence of the revenue decline indicate that customer program activity and recognized commercial output remain under pressure. Continued contraction would reduce operating leverage, make fixed platform costs harder to absorb, and delay the point at which Ginkgo’s business model can become self-funding.

Large Losses And Ongoing Cash Burn

Ginkgo continues to consume substantial cash while generating very large operating losses relative to its revenue base. Even with some improvement in expense discipline, sustained funding needs can constrain investment choices, increase dependence on external capital, and leave the company vulnerable if commercialization takes longer than expected.

Platform Maturity And Revenue Timing Risk

Remaining reliability work on Nebula could slow deployments or limit throughput as the system scales across more protocols and customers. At the same time, delivery-based revenue recognition can separate signed automation contracts from reported revenue, making growth less predictable and complicating near-term execution planning.

Ginkgo Bioworks Holdings News

DNA FAQ

What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was Mex$110.00 and its highest was Mex$289.00 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Ginkgo Bioworks Holdings’s market cap is Mex$14.19B.
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 3 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Aug 05, 2026. The company reported -Mex$14.094 earnings per share for the quarter, beating the consensus estimate of -Mex$16.819 by Mex$2.725.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -12.74.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 55,383,810 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -Mex$14.094 in its last earnings report, beating expectations of -Mex$16.819. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Hedge funds hold Ginkgo Bioworks Holdings shares: hedge funds decreased their holdings by 24.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology